# Terns Pharmaceuticals

Type: Company

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/terns-pharmaceuticals
Canonical HTML page: https://getfinancebrief.com/entity/terns-pharmaceuticals

## Recent coverage (3 stories)

### Argus Lifts Merck to $145 After 1.2M Evaxion Stake
2026-08-22 13:50:37 · Sentiment: Bullish · Impact: 6/10 · Sources: 2

Argus raised Merck's price target to $145 on pipeline depth and M&A, while Merck disclosed a small strategic stake in Evaxion. For investors, the story is the huge gap between a mega-cap's $16.6 billion quarter and a micro-cap's cash-burning AI bet.
Full story: https://getfinancebrief.com/story/merck-evaxion-argus-price-target-stake

### Merck to Acquire Terns Pharmaceuticals in $6.7B Hematology Push
2026-03-25 19:19:17 · Sentiment: Bullish · Impact: 8/10 · Sources: 2

Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a high-potential leukemia treatment. The deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its top-selling drug, Keytruda.
Full story: https://getfinancebrief.com/story/merck-terns-pharmaceuticals-acquisition-leukemia

### Merck Acquires Terns for $6.7B to Hedge Against Keytruda Patent Cliff
2026-03-25 16:35:43 · Sentiment: Bullish · Impact: 8/10 · Sources: 2

Merck has agreed to acquire Terns Pharmaceuticals for $6.7 billion in cash to bolster its oncology pipeline ahead of the 2028 patent expiration for its blockbuster drug, Keytruda. The deal centers on TERN-701, a promising leukemia treatment that positions Merck to compete directly with established players like Novartis.
Full story: https://getfinancebrief.com/story/merck-terns-acquisition-oncology-pipeline

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.